Search

Search results

4296 results found

PDX-derived organoids model in vivo drug response and secrete biomarkers.

Publication: Journal Article

Huang, Ling, Bruno Bockorny, Indranil Paul, Dipikaa Akshinthala, Pierre-Oliver Frappart, Omar Gandarilla, Arindam Bose, et al. 2020. “PDX-Derived Organoids Model in Vivo Drug Response and Secrete Biomarkers.”. JCI Insight 5 (21).

CAV1 - GLUT3 signaling is important for cellular energy and can be targeted by Atorvastatin in Non-Small Cell Lung Cancer.

Publication: Journal Article

Ali, Azhar, Elena Levantini, Chee Wai Fhu, Jun Ting Teo, John G Clohessy, Julian L Goggi, Chan-Shuo Wu, Leilei Chen, Tan Min Chin, and Daniel G Tenen. 2019. “CAV1 - GLUT3 Signaling Is Important for Cellular Energy and Can Be Targeted by Atorvastatin in Non-Small Cell Lung Cancer.”. Theranostics 9 (21): 6157-74.

An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.

Publication: Journal Article

Chen, Ming, Jiangwen Zhang, Katia Sampieri, John G Clohessy, Lourdes Mendez, Enrique Gonzalez-Billalabeitia, Xue-Song Liu, et al. 2018. “An Aberrant SREBP-Dependent Lipogenic Program Promotes Metastatic Prostate Cancer.”. Nature Genetics 50 (2): 206-18.

Characterization and analysis of the composition and dynamics of the mammalian riboproteome.

Publication: Journal Article

Reschke, Markus, John G Clohessy, Nina Seitzer, Daniel P Goldstein, Susanne B Breitkopf, Daniel B Schmolze, Ugo Ala, John M Asara, Andrew H Beck, and Pier Paolo Pandolfi. 2013. “Characterization and Analysis of the Composition and Dynamics of the Mammalian Riboproteome.”. Cell Reports 4 (6): 1276-87.

Found in translation of mTOR signaling.

Publication: Journal Article

Clohessy, John G, Markus Reschke, and Pier Paolo Pandolfi. 2012. “Found in Translation of MTOR Signaling.”. Cell Research 22 (9): 1315-8.

Pro-senescence therapy for cancer treatment.

Publication: Journal Article

Nardella, Caterina, John G Clohessy, Andrea Alimonti, and Pier Paolo Pandolfi. 2011. “Pro-Senescence Therapy for Cancer Treatment.”. Nature Reviews. Cancer 11 (7): 503-11.

The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model.

Publication: Journal Article

Cheng, Ke, Paolo Sportoletti, Keisuke Ito, John G Clohessy, Julie Teruya-Feldstein, Jeffery L Kutok, and Pier Paolo Pandolfi. 2010. “The Cytoplasmic NPM Mutant Induces Myeloproliferation in a Transgenic Mouse Model.”. Blood 115 (16): 3341-5.

Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse.

Publication: Journal Article

Sportoletti, Paolo, Silvia Grisendi, Samia M Majid, Ke Cheng, John G Clohessy, Agnes Viale, Julie Teruya-Feldstein, and Pier Paolo Pandolfi. 2008. “Npm1 Is a Haploinsufficient Suppressor of Myeloid and Lymphoid Malignancies in the Mouse.”. Blood 111 (7): 3859-62.

In Vitro Target Validation

Page

Target validation of agents or combinations of agents in cell culture in one or more murine and human tumor cell lines or mouse embryonic fibroblasts (MEFs) of various genotypes (see below). Use of several different assays depending upon the agent and type of information sought. Availability of an...

Beneficial metabolic effects of PAHSAs depend on the gut microbiota in diet-induced obese mice but not in chow-fed mice.

Publication: Journal Article

Lee, Jennifer, Kerry Wellenstein, Ali Rahnavard, Andrew T Nelson, Marlena M Holter, Bethany P Cummings, Vladimir Yeliseyev, et al. 2024. “Beneficial Metabolic Effects of PAHSAs Depend on the Gut Microbiota in Diet-Induced Obese Mice But Not in Chow-Fed Mice.”. Proceedings of the National Academy of Sciences of the United States of America 121 (28): e2318691121.